Genmab A/S (NASDAQ:GMAB) Short Interest Down 6.4% in January

Genmab A/S (NASDAQ:GMAB) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,620,000 shares, a drop of 6.4% from the January 15th total of 1,730,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.3% of the company’s stock are sold short.

Institutional Trading of Genmab A/S

Several large investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares during the period. Barclays PLC grew its stake in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after acquiring an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC increased its position in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after acquiring an additional 2,496 shares during the period. 7.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.17.

Genmab A/S Trading Up 1.8 %

NASDAQ GMAB traded up $0.38 during trading on Monday, hitting $21.30. 2,417,574 shares of the company traded hands, compared to its average volume of 1,682,134. The company has a market capitalization of $14.10 billion, a P/E ratio of 20.68, a PEG ratio of 0.54 and a beta of 0.96. The business has a fifty day simple moving average of $20.65 and a 200 day simple moving average of $23.07. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. Equities research analysts predict that Genmab A/S will post 1.25 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.